Cardeñes et al. have recently reported that ALCAM/CD166 is involved in the docking of ovarian (OvC) and colorectal (CRC) cancer-derived TEVs and in their subsequent uptake by recipient target cells. This evidence concerns the gene ALCAM and medical procedure.